A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) (ENABLE)

May 27, 2026 updated by: TG Therapeutics, Inc.

REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE)

The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Puerto Rico
      • Guaynabo, Puerto Rico, 00968
        • Recruiting
        • TG Therapeutics Investigational Trial Site
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35209
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Huntsville, Alabama, United States, 35802
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Mobile, Alabama, United States, 36604
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Arizona
      • Gilbert, Arizona, United States, 85297
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Phoenix, Arizona, United States, 85032
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Scottsdale, Arizona, United States, 85253
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • California
      • Fresno, California, United States, 93720
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Newport Beach, California, United States, 92663
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Orange, California, United States, 68130
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • West Hollywood, California, United States, 90048
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Basalt, Colorado, United States, 81621
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Colorado Springs, Colorado, United States, 80918
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Denver, Colorado, United States, 80222
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Fort Collins, Colorado, United States, 80528
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Grand Junction, Colorado, United States, 81501
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Connecticut
      • Farmington, Connecticut, United States, 06032
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Hartford, Connecticut, United States, 06112
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Delaware
      • Wilmington, Delaware, United States, 19808
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20010
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Florida
      • Altamonte Springs, Florida, United States, 32714
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Boca Raton, Florida, United States, 33486
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Clearwater, Florida, United States, 33761
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Maitland, Florida, United States, 32751
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Miami, Florida, United States, 33176
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Naples, Florida, United States, 34105
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Weston, Florida, United States, 33331
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Georgia
      • Atlanta, Georgia, United States, 30309
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Atlanta, Georgia, United States, 30327
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Smyrna, Georgia, United States, 30080
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Idaho
      • Coeur d'Alene, Idaho, United States, 83814
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Evanston, Illinois, United States, 60201
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Urbana, Illinois, United States, 61801
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Kentucky
      • Lexington, Kentucky, United States, 40504
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Louisville, Kentucky, United States, 40202
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Maryland
      • Baltimore, Maryland, United States, 21237
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Glen Burnie, Maryland, United States, 21061
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Burlington, Massachusetts, United States, 01805
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Norfolk, Massachusetts, United States, 02481
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Michigan
      • Ann Arbor, Michigan, United States, 48019
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Farmington, Michigan, United States, 48334
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Owosso, Michigan, United States, 48867
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Rochester Hills, Michigan, United States, 48307
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Montana
      • Billings, Montana, United States, 59101
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Nebraska
      • Omaha, Nebraska, United States, 68154
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Nevada
      • Las Vegas, Nevada, United States, 89106
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • New Jersey
      • Bridgewater, New Jersey, United States, 08807
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Cherry Hill, New Jersey, United States, 08002
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Freehold, New Jersey, United States, 07728
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Livingston, New Jersey, United States, 07039
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Neptune City, New Jersey, United States, 00753
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Teaneck, New Jersey, United States, 07666
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • New York
      • Amherst, New York, United States, 14226
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • New York, New York, United States, 11501
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • North Carolina
      • Charlotte, North Carolina, United States, 28210
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • New Bern, North Carolina, United States, 28562
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Raleigh, North Carolina, United States, 27607
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Ohio
      • Centerville, Ohio, United States, 45429
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Centerville, Ohio, United States, 45459
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Cincinnati, Ohio, United States, 45212
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Cleveland, Ohio, United States, 44195
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Columbus, Ohio, United States, 43214
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Toledo, Ohio, United States, 43608
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Oklahoma
      • Norman, Oklahoma, United States, 73019
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Oregon
      • Portland, Oregon, United States, 97225
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Pennsylvania
      • Bethlehem, Pennsylvania, United States, 18017
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Tennessee
      • Knoxville, Tennessee, United States, 37996
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Nashville, Tennessee, United States, 37215
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Spring Hill, Tennessee, United States, 37174
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Texas
      • Austin, Texas, United States, 78723
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Austin, Texas, United States, 78712
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Austin, Texas, United States, 78758
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Dallas, Texas, United States, 75206
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Edinburg, Texas, United States, 78572
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • San Antonio, Texas, United States, 78229
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Utah
      • Ogden, Utah, United States, 84403
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Virginia
      • Charlottesville, Virginia, United States, 22908
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Norfolk, Virginia, United States, 23502
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Vienna, Virginia, United States, 22182
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Washington
      • Kirkland, Washington, United States, 98034
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • West Virginia
      • Morgantown, West Virginia, United States, 26506
        • Recruiting
        • TG Therapeutics Investigational Trial Site
    • Wisconsin
      • Greenfield, Wisconsin, United States, 53228
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Milwaukee, Wisconsin, United States, 53226
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Neenah, Wisconsin, United States, 54956
        • Recruiting
        • TG Therapeutics Investigational Trial Site
      • Waukesha, Wisconsin, United States, 53188
        • Recruiting
        • TG Therapeutics Investigational Trial Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

The study population will include participants with RMS who are receiving BRIUMVI® (ublituximab-xiiy).

Description

Inclusion Criteria:

  1. Confirmed Multiple Sclerosis (MS) diagnosis.
  2. Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included.

Exclusion Criteria:

  1. Have received any live or live-attenuated vaccines (including for varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration or any non-live vaccines within 2 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration.
  2. Any active infection (e.g., active Hepatitis B virus [HBV])
  3. Concurrent participation in any interventional MS trials, or planned concurrent treatment with other Multiple Sclerosis Disease Modifying Therapy (MS DMT) during the study period.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
BRIUMVI® (Ublituximab-xiiy)
Participants will receive BRIUMVI® (Ublituximab-xiiy) intravenous (IV) infusion for the treatment of RMS.
Other: No Intervention
No Intervention

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Annualized Relapse Rate (ARR)
Time Frame: Up to Week 96
Up to Week 96

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Up to Week 96
Up to Week 96
Number of Participants with Infusion Related Reaction (IRR) at Each Infusion
Time Frame: Up to Week 96
Up to Week 96

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
TG Therapeutics, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 22, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 1, 2032

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 1, 2032

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 23, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 23, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 30, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 29, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 27, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • TG1101-RMS406

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Clinical Trials on No Intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings